New Holland, a brand of CNH, capped off its 130th Anniversary celebrations with the inaugural New Holland Day in Thailand, the highlight of a series of events honoring the brand’s legacy. Held at the New Holland model farm at Nakhon Sawan College of Agriculture and Technology (NSCAT), the event brought together government officials, industry partners, and media for an immersive, hands-on experience with advanced machinery and smart farming.

New Holland’s roots in Thailand trace back to its trusted Ford New Holland heritage. Across Southeast Asia, generations of farmers have relied on the durability and performance of these iconic blue tractors. 

As part of its ongoing capacity building and technology transfer to the farming community in Nakhon Sawan, New Holland provided two new tractors – a TT3.50 and a TT2.50 along with one square baler and one mulcher, for training purposes and in-field demonstration. This aims to encourage adoption of mechanized farming practices which promote sustainability and efficiency by reducing in field burning of crop residue and improving agricultural waste management. 

“Mechanization does more than increase yield. It’s a strategic investment that can help promote cleaner air, improve soil health, reduce input costs and increase farmer incomes over the long-term,” said Mark Brinn, Managing Director for Southeast Asia and Japan at CNH.

Field demonstrations underscored how New Holland machinery is expertly engineered to deliver higher productivity with fewer inputs, enabling more efficient and environmentally responsible farming practices.

New Holland, a brand of CNH, capped off its 130th Anniversary celebrations with the inaugural New Holland Day in Thailand, the highlight of a series of events honoring the brand’s legacy. Held at the New Holland model farm at Nakhon Sawan College of Agriculture and Technology (NSCAT), the event brought together government officials, industry partners, and media for an immersive, hands-on experience with advanced machinery and smart farming.

New Holland’s roots in Thailand trace back to its trusted Ford New Holland heritage. Across Southeast Asia, generations of farmers have relied on the durability and performance of these iconic blue tractors. 

As part of its ongoing capacity building and technology transfer to the farming community in Nakhon Sawan, New Holland provided two new tractors – a TT3.50 and a TT2.50 along with one square baler and one mulcher, for training purposes and in-field demonstration. This aims to encourage adoption of mechanized farming practices which promote sustainability and efficiency by reducing in field burning of crop residue and improving agricultural waste management. 

“Mechanization does more than increase yield. It’s a strategic investment that can help promote cleaner air, improve soil health, reduce input costs and increase farmer incomes over the long-term,” said Mark Brinn, Managing Director for Southeast Asia and Japan at CNH.

Field demonstrations underscored how New Holland machinery is expertly engineered to deliver higher productivity with fewer inputs, enabling more efficient and environmentally responsible farming practices.

Recent Morocco Lecture Addresses Viral Pop-Culture Phrase Referencing PRP Vaginal Injections

FAIRHOPE, Ala., Dec. 18, 2025 /PRNewswire/ — Charles Runels, MD, founder of the Cellular Medicine Association (CMA), recently delivered an international medical lecture in Morocco addressing the science behind a viral pop-culture phrase — “Revenge Vagina” — and its connection to a real, peer-reviewed medical procedure known as the O-Shot®.

Dr. Runels’ lecture examined the biological and clinical evidence behind platelet-rich plasma (PRP) injections into the female genitalia, a topic that has drawn heightened public attention following dialogue in the Hulu series All’s Fair. In the show, a character describes undergoing PRP injections as part of a post-divorce self-reinvention, prompting the now-viral phrase. Coverage of the scene by The Hollywood Reporter documents the rapid cultural adoption of the term.

According to Dr. Runels, the fictional reference reflects a medical procedure that has existed for more than a decade and continues to be actively researched, taught, and refined.

“When a pop-culture phrase suddenly captures public attention, it creates an opportunity — and a responsibility — for physicians to explain what the real medicine is and what is fiction,” said Dr. Runels. “That was the focus of my lecture in Morocco: the actual science behind what people are now calling Revenge Vagina.”

Dr. Runels first published data on the use of autologous platelet-rich plasma injections into the vagina and clitoris for the treatment of female sexual dysfunction in 2014, marking the first peer-reviewed publication describing this approach. Since that time, scientific interest has expanded substantially. A 2025 scoping review published in the Journal of Clinical Medicine identified thousands of scientific papers evaluating PRP in gynecologic and female genital applications, including sexual function, vaginal atrophy, and urinary incontinence.

The procedure discussed in Dr. Runels’ lecture is formally known as the O-Shot®, a trademarked medical protocol (USPTO Serial No. 90975954). Use of the name is restricted to physicians and physician extenders who have completed specific training and agreed to follow the documented protocol through licensure with the Cellular Medicine Association.

“PRP is not a drug and not a cosmetic filler,” Dr. Runels said. “How it is prepared, where it is injected, and why it is used matter. The O-Shot® is a defined medical protocol with more than a decade of published research and real-world clinical experience behind it.”

During the Morocco conference, Dr. Runels also presented outcomes from a large clinical cohort demonstrating sustained benefit from the O-Shot® at one year, as well as ongoing research exploring synergistic approaches that combine PRP with other therapies affecting genital blood flow and neural signaling.

To address growing public interest, the Cellular Medicine Association has published a detailed explainer summarizing the medical science discussed in the lecture and clarifying how the viral phrase relates to established clinical practice.

Dr. Runels is available for media interviews to discuss the medical science behind PRP genital injections, the distinction between licensed protocols and unregulated imitations, and how fictional portrayals intersect with evidence-based medicine.

About the Cellular Medicine Association
The Cellular Medicine Association is a nonprofit physician organization dedicated to advancing research, education, and clinical standards in regenerative medicine, including platelet-rich plasma therapies and related cellular treatments.

Contact:
Charles Runels, MD
Founder, Cellular Medicine Association
Phone: 888-920-5311
Email: 406675@email4pr.com
Web: https://www.cellularmedicineassociation.org
O-Shot® Information: https://www.oshot.info

 


Revenge Vagina

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/physician-who-coined-the-o-shot-presents-science-behind-revenge-vagina-at-international-medical-conference-302646372.html

SOURCE Cellular Medicine Association

Recent Morocco Lecture Addresses Viral Pop-Culture Phrase Referencing PRP Vaginal Injections

FAIRHOPE, Ala., Dec. 18, 2025 /PRNewswire/ — Charles Runels, MD, founder of the Cellular Medicine Association (CMA), recently delivered an international medical lecture in Morocco addressing the science behind a viral pop-culture phrase — “Revenge Vagina” — and its connection to a real, peer-reviewed medical procedure known as the O-Shot®.

Dr. Runels’ lecture examined the biological and clinical evidence behind platelet-rich plasma (PRP) injections into the female genitalia, a topic that has drawn heightened public attention following dialogue in the Hulu series All’s Fair. In the show, a character describes undergoing PRP injections as part of a post-divorce self-reinvention, prompting the now-viral phrase. Coverage of the scene by The Hollywood Reporter documents the rapid cultural adoption of the term.

According to Dr. Runels, the fictional reference reflects a medical procedure that has existed for more than a decade and continues to be actively researched, taught, and refined.

“When a pop-culture phrase suddenly captures public attention, it creates an opportunity — and a responsibility — for physicians to explain what the real medicine is and what is fiction,” said Dr. Runels. “That was the focus of my lecture in Morocco: the actual science behind what people are now calling Revenge Vagina.”

Dr. Runels first published data on the use of autologous platelet-rich plasma injections into the vagina and clitoris for the treatment of female sexual dysfunction in 2014, marking the first peer-reviewed publication describing this approach. Since that time, scientific interest has expanded substantially. A 2025 scoping review published in the Journal of Clinical Medicine identified thousands of scientific papers evaluating PRP in gynecologic and female genital applications, including sexual function, vaginal atrophy, and urinary incontinence.

The procedure discussed in Dr. Runels’ lecture is formally known as the O-Shot®, a trademarked medical protocol (USPTO Serial No. 90975954). Use of the name is restricted to physicians and physician extenders who have completed specific training and agreed to follow the documented protocol through licensure with the Cellular Medicine Association.

“PRP is not a drug and not a cosmetic filler,” Dr. Runels said. “How it is prepared, where it is injected, and why it is used matter. The O-Shot® is a defined medical protocol with more than a decade of published research and real-world clinical experience behind it.”

During the Morocco conference, Dr. Runels also presented outcomes from a large clinical cohort demonstrating sustained benefit from the O-Shot® at one year, as well as ongoing research exploring synergistic approaches that combine PRP with other therapies affecting genital blood flow and neural signaling.

To address growing public interest, the Cellular Medicine Association has published a detailed explainer summarizing the medical science discussed in the lecture and clarifying how the viral phrase relates to established clinical practice.

Dr. Runels is available for media interviews to discuss the medical science behind PRP genital injections, the distinction between licensed protocols and unregulated imitations, and how fictional portrayals intersect with evidence-based medicine.

About the Cellular Medicine Association
The Cellular Medicine Association is a nonprofit physician organization dedicated to advancing research, education, and clinical standards in regenerative medicine, including platelet-rich plasma therapies and related cellular treatments.

Contact:
Charles Runels, MD
Founder, Cellular Medicine Association
Phone: 888-920-5311
Email: 406675@email4pr.com
Web: https://www.cellularmedicineassociation.org
O-Shot® Information: https://www.oshot.info

 


Revenge Vagina

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/physician-who-coined-the-o-shot-presents-science-behind-revenge-vagina-at-international-medical-conference-302646372.html

SOURCE Cellular Medicine Association

CASABLANCA, Morocco–(BUSINESS WIRE)–500 Global, one of the world’s most active venture capital firms1, announced it has been selected to support the Ministry-led Startup VB initiative, a flagship program under the Digital Morocco 2030 strategy2. This announcement marks a significant milestone in 500 Global’s continued expansion across the African continent and its work collaborating with governments to strengthen national innovation ecosystems. Launched by the Ministry of Digital Transition a

CASABLANCA, Morocco–(BUSINESS WIRE)–500 Global, one of the world’s most active venture capital firms1, announced it has been selected to support the Ministry-led Startup VB initiative, a flagship program under the Digital Morocco 2030 strategy2. This announcement marks a significant milestone in 500 Global’s continued expansion across the African continent and its work collaborating with governments to strengthen national innovation ecosystems. Launched by the Ministry of Digital Transition a

Las Vegas Sands

Sands’ investment in the sustainability of its properties begins long before the first Team Member enters a building or the first guest arrives. The foundation laid in the company’s buildings drives sustainability forward throughout their life cycles.

Sands integrates best practices for environmental stewardship into its development process, so that resorts and other company properties are built for sustainability throughout ongoing operations. As a result, Sands has received multiple certifications for its buildings from the U.S. Green Building Council through its Leadership in Energy and Environmental Design (LEED) certification ranking system.

Introduced in 2000, the U.S. Green Building Council’s LEED ranking system was the first environmental certification in the building industry and is the most widely recognized green building rating system in the world today, with more than 195,000 projects spanning 186 countries.

Since its introduction, the LEED ranking system has become a benchmark for the design and construction of green buildings and addresses a range of factors such as energy and water use, indoor environmental quality, materials selection, and the building’s site and location within its surrounding community. LEED offers a framework for sustainable, resilient, healthy and equitable places.

Sands has a long history with this prestigious ranking system. In 2008, the company first received LEED Silver certification for New Construction for The Palazzo – the company’s former property and the first resort on the Las Vegas Strip to receive this recognition. The Palazzo was considered the largest green building in the world at the time.

Sands also earned LEED Gold certification for Existing Buildings at its formerly owned properties, The Venetian Resort Las Vegas two years later and then The Venetian Congress Center and Sands Expo in 2016.

Properties in Asia also have received LEED certification, with The Parisian Macao becoming LEED Silver certified for Building Design and Construction in 2019. Marina Bay Sands earned LEED Platinum certification for Building Operations and Maintenance for its Expo and Convention Centre in 2019 and LEED Platinum certification for Building Operations and Maintenance for the ArtScience Museum in 2024, elevating its previous LEED Gold certification.

In 2023, the company’s new corporate headquarters campus in Las Vegas earned LEED Gold certification for Building Design and Construction. With this designation, Sands extended LEED recognition for its resorts to its first standalone corporate headquarters.

The Sands ECO360 global sustainability team spearheads pursuit of LEED certifications in support of the program’s pillar for responsible building, design and development. However, numerous departments within the company must align their interests and work closely to accomplish the objectives required for LEED certifications. In designing new buildings or planning updates and modifications to existing properties, the Sands ECO360 team works closely with the company’s engineering and facilities teams to co-create plans that meet both business and environmental goals.

In addition, enhancing sustainability in building development and renovations involves incorporating smart design and technology to reduce environmental impact in ongoing operations. To guide this process, the Sands Engineering and Sustainable Development Standards (SESDS) combine engineering and sustainable development protocols into a single, comprehensive approach. Introduced in 2024, the SESDS represent collaboration among the engineering and asset management, development, facilities management and Sands ECO360 teams to unite business needs with sustainability.

The SESDS outline the minimum engineering and sustainability standards required for engineering design, selection, installation, construction and project delivery, as well as construction waste management and building materials selection. These standards apply to new construction and renovation projects globally and have been incorporated into the company’s engineering consultancy contracts.

Once resorts open or upgrades are complete, the Sands ECO360 team extends sustainable design and development by driving comprehensive processes and practices that create efficiency and reduce impact. The team continually evaluates opportunities to enhance operations, incorporate new technologies and implement best practices to improve sustainable performance.

“Pursuing LEED certification has been a priority since we opened The Palazzo and obtained our first certification, but the approach we’ve taken has continually evolved with new best practices and enhanced technology,” Katarina Tesarova, senior vice president and chief sustainability officer at Sands, said. “Our pursuit for sustainable design and property performance is never-ending.”

Las Vegas Sands

Sands’ investment in the sustainability of its properties begins long before the first Team Member enters a building or the first guest arrives. The foundation laid in the company’s buildings drives sustainability forward throughout their life cycles.

Sands integrates best practices for environmental stewardship into its development process, so that resorts and other company properties are built for sustainability throughout ongoing operations. As a result, Sands has received multiple certifications for its buildings from the U.S. Green Building Council through its Leadership in Energy and Environmental Design (LEED) certification ranking system.

Introduced in 2000, the U.S. Green Building Council’s LEED ranking system was the first environmental certification in the building industry and is the most widely recognized green building rating system in the world today, with more than 195,000 projects spanning 186 countries.

Since its introduction, the LEED ranking system has become a benchmark for the design and construction of green buildings and addresses a range of factors such as energy and water use, indoor environmental quality, materials selection, and the building’s site and location within its surrounding community. LEED offers a framework for sustainable, resilient, healthy and equitable places.

Sands has a long history with this prestigious ranking system. In 2008, the company first received LEED Silver certification for New Construction for The Palazzo – the company’s former property and the first resort on the Las Vegas Strip to receive this recognition. The Palazzo was considered the largest green building in the world at the time.

Sands also earned LEED Gold certification for Existing Buildings at its formerly owned properties, The Venetian Resort Las Vegas two years later and then The Venetian Congress Center and Sands Expo in 2016.

Properties in Asia also have received LEED certification, with The Parisian Macao becoming LEED Silver certified for Building Design and Construction in 2019. Marina Bay Sands earned LEED Platinum certification for Building Operations and Maintenance for its Expo and Convention Centre in 2019 and LEED Platinum certification for Building Operations and Maintenance for the ArtScience Museum in 2024, elevating its previous LEED Gold certification.

In 2023, the company’s new corporate headquarters campus in Las Vegas earned LEED Gold certification for Building Design and Construction. With this designation, Sands extended LEED recognition for its resorts to its first standalone corporate headquarters.

The Sands ECO360 global sustainability team spearheads pursuit of LEED certifications in support of the program’s pillar for responsible building, design and development. However, numerous departments within the company must align their interests and work closely to accomplish the objectives required for LEED certifications. In designing new buildings or planning updates and modifications to existing properties, the Sands ECO360 team works closely with the company’s engineering and facilities teams to co-create plans that meet both business and environmental goals.

In addition, enhancing sustainability in building development and renovations involves incorporating smart design and technology to reduce environmental impact in ongoing operations. To guide this process, the Sands Engineering and Sustainable Development Standards (SESDS) combine engineering and sustainable development protocols into a single, comprehensive approach. Introduced in 2024, the SESDS represent collaboration among the engineering and asset management, development, facilities management and Sands ECO360 teams to unite business needs with sustainability.

The SESDS outline the minimum engineering and sustainability standards required for engineering design, selection, installation, construction and project delivery, as well as construction waste management and building materials selection. These standards apply to new construction and renovation projects globally and have been incorporated into the company’s engineering consultancy contracts.

Once resorts open or upgrades are complete, the Sands ECO360 team extends sustainable design and development by driving comprehensive processes and practices that create efficiency and reduce impact. The team continually evaluates opportunities to enhance operations, incorporate new technologies and implement best practices to improve sustainable performance.

“Pursuing LEED certification has been a priority since we opened The Palazzo and obtained our first certification, but the approach we’ve taken has continually evolved with new best practices and enhanced technology,” Katarina Tesarova, senior vice president and chief sustainability officer at Sands, said. “Our pursuit for sustainable design and property performance is never-ending.”

LOS ANGELES, Dec. 18, 2025 /PRNewswire/ — A Los Angeles Superior Court jury has returned a $40 million verdict against Johnson & Johnson, finding that the company’s talc-based baby powder products caused ovarian cancer in two women following decades of regular use.

The verdict finding Johnson & Johnson liable for negligence, failure to warn, and fraudulent misrepresentation awarded $40 million in compensatory damages to Monica Kent, Deborah Schultz, and Dr. Albert Schultz. The cases were tried jointly in a six-week trial before a California jury.

The plaintiffs were represented by Dan Robinson of Robinson Calcagnie, Inc. and Andy Birchfield of the Beasley Allen firm. 

“This verdict reflects what the evidence made clear,” said Dan Robinson, trial counsel for the Plaintiffs Deborah and Albert Schultz. “For decades, Johnson & Johnson knew about serious safety concerns tied to its talc products and failed to warn women who trusted those products for daily personal use. We’re grateful that the jury was able to see through Defendants’ false narratives and hold them accountable for causing our clients’ ovarian cancers.”

During trial, jurors heard extensive testimony concerning Johnson & Johnson’s internal knowledge regarding the risks of talc and asbestos in its Johnson’s Baby Powder and Shower to Shower, as well as scientific and medical evidence linking long-term genital talc use to ovarian cancer. The evidence included testimony from former U.S. Food and Drug Administration Commissioner Dr. David Kessler, who outlined Johnson & Johnson’s decades-long failure to disclose critical safety information.

Jurors also heard from nationally-respected medical experts who testified about talc and asbestos found in the plaintiffs’ reproductive tracts, and peer-reviewed scientific studies showing genital use of talc significantly increases the risk of ovarian cancer.

The verdict represents a major victory for plaintiffs in California’s coordinated talc proceedings in the first talc-related ovarian cancer trial since the company’s bankruptcy filings were rejected by federal courts last year.

“We’re grateful that the jury saw through Johnson & Johnson’s confusion and returned this significant verdict both for the Schultzes and Ms. Kent, but also for the tens of thousands of women who have been harmed by Johnson’s Baby Powder,” said Paul Dagostino, trial counsel for the plaintiffs.

The cases are Deborah Schultz et al. v. Johnson & Johnson et al., Case No. 20CV0476, and Monica Kent v. Johnson & Johnson et al., Case No. 17CV318672, which were pending in the California State Court Coordinated Proceeding JCCP No. 4872, Johnson & Johnson Talcum Powder Cases.

About Robinson Calcagnie, Inc.

Robinson Calcagnie, Inc. is a nationally recognized plaintiffs’ law firm based in Newport Beach, California, focused on complex litigation involving dangerous products, corporate misconduct, environmental harm, and catastrophic injury. The firm is known for its trial-driven approach and commitment to holding powerful defendants accountable. Learn more about Robinson Calcagnie, Inc. at www.robinsonfirm.com.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/los-angeles-jury-delivers-40-million-verdict-against-johnson–johnson-in-talcum-powder-ovarian-cancer-trial-302646356.html

SOURCE Robinson Calcagnie, Inc.

LOS ANGELES, Dec. 18, 2025 /PRNewswire/ — A Los Angeles Superior Court jury has returned a $40 million verdict against Johnson & Johnson, finding that the company’s talc-based baby powder products caused ovarian cancer in two women following decades of regular use.

The verdict finding Johnson & Johnson liable for negligence, failure to warn, and fraudulent misrepresentation awarded $40 million in compensatory damages to Monica Kent, Deborah Schultz, and Dr. Albert Schultz. The cases were tried jointly in a six-week trial before a California jury.

The plaintiffs were represented by Dan Robinson of Robinson Calcagnie, Inc. and Andy Birchfield of the Beasley Allen firm. 

“This verdict reflects what the evidence made clear,” said Dan Robinson, trial counsel for the Plaintiffs Deborah and Albert Schultz. “For decades, Johnson & Johnson knew about serious safety concerns tied to its talc products and failed to warn women who trusted those products for daily personal use. We’re grateful that the jury was able to see through Defendants’ false narratives and hold them accountable for causing our clients’ ovarian cancers.”

During trial, jurors heard extensive testimony concerning Johnson & Johnson’s internal knowledge regarding the risks of talc and asbestos in its Johnson’s Baby Powder and Shower to Shower, as well as scientific and medical evidence linking long-term genital talc use to ovarian cancer. The evidence included testimony from former U.S. Food and Drug Administration Commissioner Dr. David Kessler, who outlined Johnson & Johnson’s decades-long failure to disclose critical safety information.

Jurors also heard from nationally-respected medical experts who testified about talc and asbestos found in the plaintiffs’ reproductive tracts, and peer-reviewed scientific studies showing genital use of talc significantly increases the risk of ovarian cancer.

The verdict represents a major victory for plaintiffs in California’s coordinated talc proceedings in the first talc-related ovarian cancer trial since the company’s bankruptcy filings were rejected by federal courts last year.

“We’re grateful that the jury saw through Johnson & Johnson’s confusion and returned this significant verdict both for the Schultzes and Ms. Kent, but also for the tens of thousands of women who have been harmed by Johnson’s Baby Powder,” said Paul Dagostino, trial counsel for the plaintiffs.

The cases are Deborah Schultz et al. v. Johnson & Johnson et al., Case No. 20CV0476, and Monica Kent v. Johnson & Johnson et al., Case No. 17CV318672, which were pending in the California State Court Coordinated Proceeding JCCP No. 4872, Johnson & Johnson Talcum Powder Cases.

About Robinson Calcagnie, Inc.

Robinson Calcagnie, Inc. is a nationally recognized plaintiffs’ law firm based in Newport Beach, California, focused on complex litigation involving dangerous products, corporate misconduct, environmental harm, and catastrophic injury. The firm is known for its trial-driven approach and commitment to holding powerful defendants accountable. Learn more about Robinson Calcagnie, Inc. at www.robinsonfirm.com.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/los-angeles-jury-delivers-40-million-verdict-against-johnson–johnson-in-talcum-powder-ovarian-cancer-trial-302646356.html

SOURCE Robinson Calcagnie, Inc.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.